Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
GMPPA defects cause a neuromuscular disorder with α-dystroglycan hyperglycosylation
Patricia Franzka, … , Julia von Maltzahn, Christian A. Hübner
Patricia Franzka, … , Julia von Maltzahn, Christian A. Hübner
Published March 23, 2021
Citation Information: J Clin Invest. 2021;131(9):e139076. https://doi.org/10.1172/JCI139076.
View: Text | PDF
Research Article Muscle biology

GMPPA defects cause a neuromuscular disorder with α-dystroglycan hyperglycosylation

  • Text
  • PDF
Abstract

GDP-mannose-pyrophosphorylase-B (GMPPB) facilitates the generation of GDP-mannose, a sugar donor required for glycosylation. GMPPB defects cause muscle disease due to hypoglycosylation of α-dystroglycan (α-DG). Alpha-DG is part of a protein complex, which links the extracellular matrix with the cytoskeleton, thus stabilizing myofibers. Mutations of the catalytically inactive homolog GMPPA cause alacrima, achalasia, and mental retardation syndrome (AAMR syndrome), which also involves muscle weakness. Here, we showed that Gmppa-KO mice recapitulated cognitive and motor deficits. As structural correlates, we found cortical layering defects, progressive neuron loss, and myopathic alterations. Increased GDP-mannose levels in skeletal muscle and in vitro assays identified GMPPA as an allosteric feedback inhibitor of GMPPB. Thus, its disruption enhanced mannose incorporation into glycoproteins, including α-DG in mice and humans. This increased α-DG turnover and thereby lowered α-DG abundance. In mice, dietary mannose restriction beginning after weaning corrected α-DG hyperglycosylation and abundance, normalized skeletal muscle morphology, and prevented neuron degeneration and the development of motor deficits. Cortical layering and cognitive performance, however, were not improved. We thus identified GMPPA defects as the first congenital disorder of glycosylation characterized by α-DG hyperglycosylation, to our knowledge, and we have unraveled underlying disease mechanisms and identified potential dietary treatment options.

Authors

Patricia Franzka, Henriette Henze, M. Juliane Jung, Svenja Caren Schüler, Sonnhild Mittag, Karina Biskup, Lutz Liebmann, Takfarinas Kentache, José Morales, Braulio Martínez, Istvan Katona, Tanja Herrmann, Antje-Kathrin Huebner, J. Christopher Hennings, Susann Groth, Lennart Gresing, Rüdiger Horstkorte, Thorsten Marquardt, Joachim Weis, Christoph Kaether, Osvaldo M. Mutchinick, Alessandro Ori, Otmar Huber, Véronique Blanchard, Julia von Maltzahn, Christian A. Hübner

×

Figure 7

Hyperglycosylation and decreased abundance of α-DG in KO mice and in patients with AAMR syndrome.

Options: View larger image (or click on image) Download as PowerPoint
Hyperglycosylation and decreased abundance of α-DG in KO mice and in pat...
(A) Signals for the α-DG core were decreased in skeletal muscle sections of Gmppa-KO mice at 12 months of age. Overviews and control staining after deglycosylation with PNGase F are shown in Supplemental Figure 5. (B) β-DG signals were unchanged. Scale bars (A and B): 5 μm. (C) Skeletal muscle α-DG abundance was decreased in 12-month-old KO mice; β-DG abundance was unchanged (n = 5 per group; 2-way ANOVA with Bonferroni post hoc test). Vinculin and GAPDH served as loading control. The quantification after enzymatic deglycosylation is shown in Supplemental Figure 5C. (D and E) Immunostaining of cross-sections of musculus quadriceps femoris biopsies from patients (P1, P2) for the glycosylation-specific α-DG epitopes. (D) IIH6C4 and (E) VIA4 showed increased signal intensities compared with the control. (F) Signal intensities for the α-DG core protein were decreased in patients. (G) β-DG signal intensities were unchanged. (H) In patients, laminin signals appear irregular (arrowheads). Scale bars (D–H): 50 μm. (I) Immunoblot analyses of skeletal muscle lysates showed decreased band intensities for GMPPA and the α-DG core in patient samples; signals for oligomannose, PNA, and the glycosylation-specific α-DG epitope were increased. Note the shift of the bands for α-DG to a larger size in patients. The signals for Con A, β-DG, and laminin were unchanged. GAPDH served as loading control. Additional loading controls are displayed in Supplemental Figure 7. (J) The regular α-actinin staining pattern was almost absent in patient samples. Scale bars: 10 μm. (K) The ultrastructural analyses revealed disarranged myofibers and irregular Z-discs in patients. Scale bars: 500 nm. Quantitative data are presented as mean ± SEM with individual data points. **P < 0.005.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts